Key Takeaways:
Halozyme Therapeutics (NASDAQ: HALO) reported first-quarter revenue surged 42% on robust royalty growth and announced a new $1 billion share repurchase plan.
"We started 2026 with exceptional momentum," Halozyme President and CEO Helen Torley said, citing the performance of approved partner products and an expanding clinical pipeline.
The biopharmaceutical company posted strong results that surpassed Wall Street expectations for the quarter ended March 31. Revenue grew to $376.7 million, beating the consensus estimate of $357.73 million, while non-GAAP diluted earnings per share of $1.60 topped the average analyst projection of $1.54.
Shares of Halozyme have underperformed the S&P 500 this year, losing about 4.7% year-to-date. The new buyback authorization, equivalent to a 3% annual yield over several years by company estimates, and strong guidance may help bolster investor confidence.
The company’s performance was driven by a 43% year-over-year increase in royalty revenue to $240.7 million. This growth comes from its ENHANZE drug-delivery technology, used in therapies including Johnson & Johnson’s DARZALEX and argenx’s VYVGART Hytrulo. Royalties from DARZALEX rose 26% to $129 million, while royalties from VYVGART Hytrulo jumped 119% to $46.3 million.
Under its new capital allocation plan, Halozyme will return capital to shareholders via the $1 billion buyback program, with at least $400 million in repurchases expected in 2026. The company also plans to continue deleveraging and evaluate drug-delivery acquisition opportunities, though management noted a deal is unlikely this year.
Halozyme reaffirmed its full-year 2026 guidance, continuing to expect total revenue of $1.71 billion to $1.81 billion and non-GAAP diluted EPS of $7.75 to $8.25. The company projects its ENHANZE royalties will exceed $1 billion for the first time in 2026, a key milestone for its core platform.
The strong quarterly performance and shareholder return program signal management's confidence in sustained growth from its ENHANZE platform. Investors will watch for continued execution on its 2026-2028 financial outlook and progress in developing its newer Hypercon platform.
This article is for informational purposes only and does not constitute investment advice.
